CytomX Therapeutics (CTMX) awards 118,000 stock options to board director

Rhea-AI Filing Summary

CytomX Therapeutics director Charles S. Fuchs received a grant of stock options covering 118,000 shares of common stock, with an exercise price of $3.24 per share and an expiration date of July 23, 2036. 1/36th of the shares vest on each monthly anniversary starting July 24, 2026, so all options vest over three years, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fuchs Charles S.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	118,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 118,000 shares (Direct)

Footnotes (1)

1. F1. 1/36th of the shares subject to the option vest on each monthly anniversary measured from July 24, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Key Figures

Options granted: 118,000 shares Exercise price: $3.2400 per share Expiration date: July 23, 2036 +1 more

4 metrics

Options granted 118,000 shares Stock options awarded to Charles S. Fuchs on July 24, 2026

Exercise price $3.2400 per share Exercise price of the stock option grant

Expiration date July 23, 2036 Expiration of the reported stock option grant

Vesting period 36 months 1/36th of shares vest monthly from July 24, 2026 until fully vested

Key Terms

Stock Option (Right to Buy), Vesting Commencement Date, exercise price

3 terms

Stock Option (Right to Buy) financial

"Security title reported as Stock Option (Right to Buy)"

Vesting Commencement Date financial

"Measured from July 24, 2026, the Vesting Commencement Date"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

exercise price financial

"Conversion or exercise price of $3.2400 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 05:07 PM Accepted by SEC EDGAR 07/30/2026 - 05:07 PM Learn about SEC filing dates

FAQ

What insider transaction did CTMX director Charles S. Fuchs report?

Charles S. Fuchs reported receiving a stock option grant from CytomX Therapeutics covering 118,000 shares of common stock. The options are a form of director compensation, not a market purchase of existing CTMX shares.

How many CytomX (CTMX) stock options were granted and at what exercise price?

The grant to Charles S. Fuchs covers 118,000 shares of CytomX common stock with an exercise price of $3.24 per share. This price is the cost to acquire each share if and when he exercises the options.

When do the CTMX options granted to Charles S. Fuchs begin vesting and fully vest?

The options begin vesting on July 24, 2026, the vesting commencement date. 1/36th of the shares vest monthly, so the grant becomes fully vested on the third anniversary of that date, assuming he continues serving CytomX.

What is the expiration date of the CytomX (CTMX) stock options granted to Charles S. Fuchs?

The stock options granted to Charles S. Fuchs expire on July 23, 2036. After that date, any unexercised options will lapse and can no longer be used to purchase CytomX common shares.

Is the CTMX insider transaction a market trade or an equity award?

This CTMX insider event is an equity award, not a market trade. It is coded as a grant or award acquisition (transaction code A), reflecting compensation in the form of stock options rather than open-market buying or selling.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fuchs Charles S.

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.24	07/24/2026		A		118,000		(1)	07/23/2036	Common Stock	118,000	$0	118,000	D

Explanation of Responses:

1. 1/36th of the shares subject to the option vest on each monthly anniversary measured from July 24, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

	/s/ Christopher Ogden, as Attorney-in-Fact for Charles S. Fuchs	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)